Atlas Trials

OncoC4, Inc.

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch OncoC4, Inc.

RecordFirmDate
Gotistobart Long Term Extension (LTE) Study (NCT07659379)OncoC4, Inc.2026-07-01
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (NCT07408258)OncoC4, Inc.2026-06-01
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors (NCT06635785)OncoC4, Inc.2025-03-26
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors (NCT06352359)OncoC4, Inc.2024-08-23
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 (NCT06219499)OncoC4, Inc.2024-06-01
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (NCT05682443)OncoC4, Inc.2023-12-11
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (NCT05858736)OncoC4, Inc.2023-07-11
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (NCT05671510)OncoC4, Inc.2023-06-28
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (NCT05446298)OncoC4, Inc.2022-12-22
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526)OncoC4, Inc.2020-09-16

Track OncoC4, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.